Aelis Farma

About:

Aelis Farma is a biotech company conducting research and development on innovative signaling specific drugs

Website: https://www.aelisfarma.com/

Top Investors: Bpifrance, National Institute on Drug Abuse (NIDA), Région Nouvelle-Aquitaine, Inserm Transfert Initiative, NACO

Description:

Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways. Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

Total Funding Amount:

30.5M EUR

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Bordeaux, Aquitaine, France

Founded Date:

2013-01-01

Contact Email:

contact(AT)aelisfarma.com

Founders:

Giovanni Marsicano, Pier Vincenzo Piazza, Sandy Fabre, Stéphanie Monlezun, Valérie Scappaticci

Number of Employees:

11-50

Last Funding Date:

2024-07-31

IPO Status:

Public

Industries:

© 2025 bioDAO.ai